Collegeville’s Pfizer Reaches Agreement with Experimental COVID-19 Drug in Low-Income Nations

Medicines Patent Pool. pic 2021, Paxlovid
Image via Medicines Patent Pool.
With this agreement, the experimental COVID-19 drug may be more readily available in lower-income countries.

Pfizer, a pharmaceutical giant with a significant presence in Collegeville, has agreed to share the license of its experimental COVID-19 drug, potentially opening up the treatment to millions of people in low-income nations, write Adam Taylor and Claire Parker for The Philadelphia Inquirer.

According to Pfizer, the pill regimen called Paxlovid reduces the risk of COVID-19-related hospitalization or death by 89 percent when taken within three days of the onset of symptoms.

The pill has yet to receive regulatory approval in the United States, but the company is planning to seek authorization from the Food and Drug Administration soon.

Pfizer reached an agreement with Medicines Patent Pool, the nonprofit group that is backed by the United Nations and works toward facilitating global access to life-saving medicines.

“This license is so important because, if authorized or approved, this oral drug Paxlovid is particularly well-suited for low- and middle-income countries and could play a critical role in saving lives, contributing to global efforts to fight the current pandemic,” said Charles Gore, executive director of Medicines Patent Pool.

This deal would make it possible for manufacturers to supply countries that make up around 53 percent of the world’s population.

Read more about Pfizer and Paxlovid in The Philadelphia Inquirer.